Form 4: Skye Bioscience Director Andrew J. Schwab Reports Sale of Common Stock

Director Andrew J. Schwab reports the sale of Skye Bioscience (SKYE) common stock through affiliated entities, 5AM Ventures, in multiple transactions.

Summary

• Andrew J. Schwab, a director of Skye Bioscience, reported the sale of common stock on September 11 and 13, 2024.
• The sales were executed through affiliated entities: 5AM Ventures VII, L.P., 5AM Ventures II, L.P., and 5AM Co-Investors II, L.P.
• On September 11, shares were sold at a price of $6.6.
• On September 13, shares were sold at prices ranging from $6.05 to $6.11.
• After these transactions, the total shares beneficially owned by 5AM Ventures VII, L.P. is 8,167,206, by 5AM Ventures II, L.P. is 1,679,685, and by 5AM Co-Investors II, L.P. is 66,277.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the director selling shares, which could indicate a lack of confidence or a need to liquidate holdings. However, the filing itself is a routine disclosure.

Negatives

• A director is selling shares, which could be interpreted negatively by the market.

Risks

• Continued selling pressure from the director's affiliated entities could negatively impact the stock price.

Industry Context

Form 4 filings are routine disclosures for insiders, but the market often scrutinizes them for signals about a company's prospects. Large insider sales can sometimes raise concerns, while insider purchases are often seen as a positive sign.

Stakeholder Impact

• Shareholders may react to the news of the director's stock sale.

Key Dates